Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Selenocysteine dependency renders central nervous system leukaemia therapeutically sensitive to ferroptosis

Nikolai Gajic, Rhona Christie, Shirley Lam et al. Nov 03, 2025 pp. 1526-1526 10.1182/blood-2025-1526

Abstract Background and significance: Central nervous system (CNS) directed therapy in acute lymphoblastic leukemia (ALL) remains a formidab...

BPI-2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1-overexpressing AML In Vivo

Lucio Pinheiro, Isabel Weinhäuser, Diego Pereira-Martins et al. Nov 03, 2025 pp. 5066-5066 10.1182/blood-2025-5066

Abstract Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the accumulation of immature myeloid cells in...

Phase 1, open-label, multi-center trial of RPT1G in patients with Relapsed/Refractory Acute Myeloid Leukemia and high-risk Myelodysplastic Syndromes/neoplasms

Dennise De Jesús-Díaz, Aaron Goldberg, Esteban Abella et al. Nov 03, 2025 pp. 5208-5208 10.1182/blood-2025-5208

Abstract Background: Nicotinamide phosphoribosyltransferase (NAMPT) controls how cells use energy and is central to human biology. NAMPT is...

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

Michelle Nwachukwu, Farhad Ravandi, Sanam Loghavi et al. Nov 03, 2025 pp. 1620-1620 10.1182/blood-2025-1620

Abstract Background: The CUX1 gene, known as CUT-like homeobox 1, is located on chromosome 7q22.1 and encodes several protein isoforms, part...

Adherence to the 2018 world cancer research fund/American institute for cancer research cancer prevention recommendations and mortality among blood cancer survivors

LaShae Rolle, Harleen Kaur, Melissa Lopez-Pentecost et al. Nov 03, 2025 pp. 4538-4538 10.1182/blood-2025-4538

Abstract Background: Survivors of hematologic malignancies face elevated mortality risk, yet the impact of modifiable lifestyle factors on t...

Single-center retrospective analysis of maribavir in the treatment of refractory and drug-intolerant cytomegalovirus viremia and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Wei Ma, Xingyu Cao, Jiarui Zhou et al. Nov 03, 2025 pp. 6059-6059 10.1182/blood-2025-6059

Abstract Background Cytomegalovirus (CMV) infection is a common complication following allogeneic hematopoietic stem cell transplantation (a...

Combined KIT D816V and HαT blood testing: Development and validation of a targeted non-invasive work-up to guide invasive testing for systemic mastocytosis

Daniel Koch, Dagmar von Bubnoff, Deborah Christen et al. Nov 03, 2025 pp. 5586-5586 10.1182/blood-2025-5586

Abstract Background: Systemic Mastocytosis (SM) is a rare myeloid neoplasm (prevalence of 0.01%) characterized by a clonal mast cell expansi...

Low incidence of agvhd with ptcy, tacrolimus and post-engraftment low dose ATG-based GvHD prophylaxis in haplo-identical donor transplantation and establish of new predict score for grade II-iv agvhd

Lining Wang, Wenhui Gao, Jieling Jiang et al. Nov 03, 2025 pp. 4224-4224 10.1182/blood-2025-4224

Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for hematological malignancies while acute graft-ve...

Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma

Rajib Shome, Srikanth Talluri, Diana Cirstea et al. Nov 03, 2025 pp. 3952-3952 10.1182/blood-2025-3952

Abstract Background: Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell disorder with high risk of progression, characterized b...

Baseline characterization of nutrition counseling and modifiable cardiovascular risk factors among childhood cancer survivors through EHR-linked data analytics

Manuel Gonzales, Kimberly Davidow Nov 03, 2025 pp. 6276-6276 10.1182/blood-2025-6276

Abstract Background: Approximately 50% of childhood cancer survivors (CCS) will develop therapy-related cardiovascular (...

Single-dose IV ferric derisomaltose improves hematologic and patient-reported outcomes in pregnant individuals with iron deficiency anemia

Thalia Padilla Kelley, Kylee Martens, Monica Rincon et al. Nov 03, 2025 pp. 4682-4682 10.1182/blood-2025-4682

Abstract Background: Iron deficiency anemia (IDA) affects over 40% of pregnancies worldwide and is associated with fatigue, reduced quality...

Development of a novel multiomic sequencing approach to characterize infused donor memory-like NK cells in an immune compatible environment

Roman Shapiro, Grace Birch, Chen Weng et al. Nov 03, 2025 pp. 2352-2352 10.1182/blood-2025-2352

Abstract Background Cytokine-induced memory-like natural killer (mem-NK) cells have an enhanced capacity for proliferation and persistence c...

Chronic myeloid leukemia (CML) evolution is not encoded in single-cell microstates, but emerges from population-level macrostates

David Frankhouser, Dandan Zhao, Yu-Hsuan Fu et al. Nov 03, 2025 pp. 5026-5026 10.1182/blood-2025-5026

Abstract CML progression is defined by increased disease burden and potential for transformation to blastic phase (BP), yet the mechanisms a...

Incidence of severe infections in patients with multiple myeloma treated with immunoglobulin-replacement therapy

Elisabet Viayna, Jiani Zhou, James Jordan et al. Nov 03, 2025 pp. 4576-4576 10.1182/blood-2025-4576

Abstract Introduction: Secondary immunodeficiency (SID) is an increasing concern in patients with multiple myeloma (MM). SID may be caused b...

Molecular subclusters across the continuum of myelodysplastic neoplasms and acute myeloid leukaemia define distinct clinical entities

Daniel Painter, Simon Crouch, Paul Glover et al. Nov 03, 2025 pp. 3869-3869 10.1182/blood-2025-3869

Abstract Introduction The distinction between myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML) is becom...

What can PTEN expression tell us about CML progression?

Luciana Nardinelli, Katia Pagnano, Carmino De Souza et al. Nov 03, 2025 pp. 6762-6762 10.1182/blood-2025-6762

Abstract The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the natural course of Chronic Myeloid Leukemia (CML), sign...

Real-world treatment patterns of elranatamab in patients with multiple myeloma in Japan: Findings from the EVEREST study

Satoshi Yoshihara, Aster Meche, Patrick Hlavacek et al. Nov 03, 2025 pp. 2801-2801 10.1182/blood-2025-2801

Abstract Background Elranatamab is a B-cell maturation antigen (BCMA)-CD3–directed bispecific antibody approved in Japan for the treatment o...

High-throughput screening uncloaks actionable compounds for ttmv::rara AML

Zhanrui Cheng, Shu Sun, Jiayu Wang et al. Nov 03, 2025 pp. 6109-6109 10.1182/blood-2025-6109

Abstract Abstract Acute myeloid leukemia (AML) with TTMV::RARA fusion, which exhibits clinical features resembling acute promyelocytic leuke...

Pregnancy and delivery outcomes in women with Hemophilia A and B: A multicenter cohort study from the Italian association of haemophilia centers

Mariasanta Napolitano, Marta Mattana, Claudia Cammarata et al. Nov 03, 2025 pp. 3073-3073 10.1182/blood-2025-3073

Abstract Introduction: Hemophilia A and B are traditionally recognized as X-linked recessive disorders that primarily affect males. However,...

BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial

Shlomo Elias, Hadass Pri Chen, Shlomit Kfir-Erenfeld et al. Nov 03, 2025 pp. 2378-2378 10.1182/blood-2025-2378

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy offers a promising, targeted approach for treating severe, refractory...

EBV status of lymphoma specimens from Ethiopia: Initial categorization of pathology and epigenetic state of EBV

Seifegebriel Feleke, Robert Baiocchi, Christoph Weigel et al. Nov 03, 2025 pp. 7056-7056 10.1182/blood-2025-7056

Abstract Background: Epstein-Barr virus (EBV) is an oncogenic herpesvirus that infects nearly all individuals by adulthood, with over 90% of...

Selinexor enhances the effect of venetoclax on Acute Myeloid Leukemia stem and progenitor cells by disrupting lysosomal function

Ran Zhao, Hongwei Peng, Jiaqi Wan et al. Nov 03, 2025 pp. 3290-3290 10.1182/blood-2025-3290

Abstract Background: AML is a hematologic malignancy that originates from leukemia stem cells (LSCs) which maintain their self-renewal abilit...

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Krischan Braitsch, Karin Huber, Andrew Berdel et al. Nov 03, 2025 pp. 2846-2846 10.1182/blood-2025-2846

Abstract Introduction Mutations in IDH1 or IDH2 occur in 15-20% of acute myeloid leukemia (AML) cases and promote leukem...

Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis

Mengran Chen, Ying Qu, Yu Wu Nov 03, 2025 pp. 2991-2991 10.1182/blood-2025-2991

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome driven by aberrantly activ...

Favorable outcomes including post-transplant survival are seen independent of baseline skin burden in treatment-naïve patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subgroup analysis of a pivotal Trial

Eunice Wang, Andrew Lane, Anthony Selwyn Stein et al. Nov 03, 2025 pp. 5221-5221 10.1182/blood-2025-5221

Abstract Introduction BPDCN is an aggressive orphan malignancy characterized by CD123 expression and involvement of the skin, bone marrow (B...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page